graph Evidence gap map comparisons
atezolizumab based treatmentavelumab based treatmentnivolumab based treatmentpembrolizumab based treatmentImmune checkpoint association
atezolizumab alone atezolizumab plus bevacizumab avelumab plus axitinib nivolumab plus cabozantinib pembrolizumab plus axitinib pembrolizumab plus lenvatinib nivolumab plus ipilimumab
mRCC - L1 - PDL1 negative 1   
mRCC - L1 - PDL1 positive 4        
Comparator:  vs sunitinib; 
Risk of bias:  low;   some concerns;   high;  NA;